Why Nephros, Inc.’s (NEPH) Stock Is Down 5.51%
As of Monday, August 17, Nephros, Inc.’s NEPH share price has dipped by 5.51%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Commentary & Analysis
Why Nephros, Inc.’s (NEPH) Stock Is Down 9.81%
As of Friday, August 14, Nephros, Inc.’s NEPH share price has dipped by 9.81%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nephros, Inc.’s (NEPH) Stock Is Down 6.07%
As of Wednesday, January 21, Nephros, Inc.’s NEPH share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Nephros, Inc.’s (NEPH) Stock Is Up 6.16%
As of Monday, December 22, Nephros, Inc.’s NEPH share price has surged by 6.16%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Nephros, Inc.’s (NEPH) Stock Is Up 5.11%
As of Tuesday, December 09, Nephros, Inc.’s NEPH share price has surged by 5.11%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | NEPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $45.8 | $3,693.2 | 15% |
|
| Shares Out (Mil) | 11.1 | 45.7 | 22% |
|
| Institutional Ownership | 78.5% | 73.4% | 47% |
|
| Float (Mil) | 9.4 | 58.0 | 18% |
|
| Beta | 1.53 | 1.13 | 83% |
|
| Avg Daily Volume (000s) | 45 | 206 | 27% |
|
| Price Change (52-week) |
1.0% | 77.6% | 47% |
|
| Growth | NEPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.9% | 5.5% | 77% |
|
| Net Income (5yr) | 17.6% | 9.5% | 69% |
|
| EPS (5yr) | 17.2% | 11.3% | 63 |
|
| Dividends (5yr) | 0.0% | 1.3% | 0% |
|
| Cash Flow (5yr) | (19.7%) | (16.1%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.030 | $0.170 | $0.210 | |
| Month Ago EPS | $0.020 | $0.040 | $0.145 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.025 | $0.045 | $0.100 | |
| Year/Year Chg | (72.7%) | 54.5% | 190.9% | |
| Financials | NEPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $21 | $2,054 | 13% |
|
| Net Income (TTM) (Mil) | $2 | $144 | 41% |
|
| EPS (TTM) | $0.162 | $1.300 | 45% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | $218 | 31% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $451 | 15% |
|
| Enterprise Value (Q1) (Mil) | $46 | $4,026 | 16% |
|
| Valuation | NEPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.84 | 2.34 | 71% |
|
| P/E | 26.4 | 27.4 | 64% |
|
| Dividend Yield | 0.0% | 0.3% | 0% |
|
| PEG (5yr hist) | 1.5 | 1.4 | 60% |
|
| Ratios | NEPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.3% | 31.8% | 74% |
|
| Net Margin | 8.4% | 7.1% | 58% |
|
| ROA | 12.4% | 4.7% | 91% |
|
| ROE | 16.1% | 10.1% | 73% |
|
| Liabilities to Assets | 24.1% | 49.8% | 16% |
|
| F-Score | 4 | 5 | 33% |
|
Nephros, Inc. did not pass any screens on 8/25/2026.
